Rendering

Component: (Network and Table)
Network
2413403 - Disclosure - Income Taxes Income Taxes - Components of the Company's Deferred Tax Assets (Details)
(http://www.acceleronpharma.com/role/IncomeTaxesIncomeTaxesComponentsOfCompanysDeferredTaxAssetsDetails)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001280600 (http://www.sec.gov/CIK)
Income Tax Disclosure [Abstract]Period [Axis]
2016-12-31
2015-12-31
Income Tax Disclosure [Abstract]
 
 
U.S. and state net operating loss carryforwards
109,429,000  
90,732,000  
Research and development credits
9,717,000  
7,864,000  
Deferred revenue
1,666,000  
1,883,000  
Accruals and other temporary differences
15,725,000  
9,319,000  
Total deferred tax assets
136,537,000  
 
109,798,000  
 
Less valuation allowance
(136,537,000) 
(109,798,000) 
Net deferred tax assets
0  
 
0